Form 4: Prelude Therapeutics Director Paul Friedman Acquires Stock Options
SEC Form 4
Director Paul Friedman acquired 23,500 stock options in Prelude Therapeutics on June 14, 2024.
Summary
- On June 14, 2024, Paul A Friedman, a director of Prelude Therapeutics Inc., acquired 23,500 stock options.
- The options have an exercise price of $3.90.
- The options will fully vest upon the earlier of the Issuer's next annual stockholder meeting, or the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- The options expire on June 13, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign by shareholders, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of transaction: Paul Friedman acquired 23,500 stock options. |
| 06/13/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.